A physician associate in an understaffed emergency department diagnosed a patient’s severe back pain as sciatica after a CT scan read as normal. Five days later, a different clinician identified a perirectal abscess that had already progressed to require multiple surgeries.

The FDA approved cefepime-zidebactam (Zaynich) for complicated UTI and pyelonephritis caused by susceptible gram-negative organisms. Approval followed phase 3 trial data showing higher rates of symptom and microbiologic resolution compared with meropenem in hospitalized adults.

A network meta-analysis of 32 randomized trials found long-term, high-dose vitamin D supplementation added to standard multiple sclerosis therapy reduced relapse risk and eased disability progression, while short-term use showed no significant effect.

A BMJ systematic review of 69 trials found calcium and vitamin D supplementation provided little to no reduction in fracture or fall risk among nearly 154,000 older adults studied.

A first joint EULAR/PReS guideline unifies systemic juvenile idiopathic arthritis and adult-onset Still’s disease under a single name, Still’s disease, and recommends early IL-1 or IL-6 inhibitor therapy over prolonged glucocorticoid use.

The FDA has approved the first generic version of baloxavir marboxil, a single-dose influenza antiviral noninferior to oseltamivir, ahead of the 2026-2027 flu season.